Gyre Therapeutics, Inc. Exchange Rate Effect on Cash
Gyre Therapeutics, Inc. (GYRE) reported Exchange Rate Effect on Cash of $928.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-07
- Gyre Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2026-03-31 was $285.00K, a 470.00% increase year-over-year.
- Gyre Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2025-03-31 was $50.00K.
- Gyre Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2024-03-31 was -$46.00K, a 123.00% decline year-over-year.
- Gyre Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2023-03-31 was $200.00K.
- Gyre Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2025 was $343.00K.
- Gyre Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2024 was -$273.00K.
- Gyre Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2023 was -$298.00K.
- Gyre Therapeutics, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2022 was -$1.89M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $928.00K 10-Q · filed 2026-08-07 | ||||
| 2026-03-31 | $285.00K 10-Q · filed 2026-05-08 | ||||
| 2025-12-31 | $343.00K 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $216.00K 10-Q · filed 2025-11-07 | ||||
| 2025-06-30 | $10.00K 10-Q · filed 2026-08-07 | $99.00K 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $50.00K 10-Q · filed 2026-05-08 | ||||
| 2024-12-31 | -$273.00K 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | -$18.00K 10-Q · filed 2025-11-07 | ||||
| 2024-06-30 | -$124.00K 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | -$46.00K 10-Q · filed 2025-05-09 | ||||
| 2023-12-31 | -$298.00K 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | -$529.00K 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | -$700.00K 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | -$1.89M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |